Nineteen out of every 100,000 Americans each year will get an eye inflammation called uveitis — and for a long time, doctors have had only blunt tools to treat it. Now scientists in Chicago may have found a smarter way.
Researchers at Northwestern University in Chicago published a study in The American Journal of Pathology that cracks open a key mystery: how immune cells sneak into the eye. White blood cells are the body's repair crew, but getting them into the retina — the tissue that lines the back of the eye and lets us see — is no easy trip. The retina sits behind a highly protected wall called the blood-retinal barrier, part of the same shield that guards the brain.
The surprising finding? Despite that special protection, white blood cells enter the eye using the exact same doorway they use everywhere else in the body. That gateway is a protein called PECAM (short for platelet endothelial cell adhesion molecule). Think of PECAM as the front gate of a walled city: when immune cells need to get inside to fight an infection, PECAM opens the way.
To study this, the team injected a bacterial toxin into the eyes of mice to mimic infection, then watched what happened hour by hour. Neutrophils — the fire brigade of the immune system — rushed in first. Within 48 hours they were nearly gone, but they had already called in a backup crew of cells called monocytes. Those monocytes matured into macrophages and stayed in the retina for at least 72 hours, cleaning up after the fire.
Here's where it gets curious. When the researchers removed neutrophils from the blood on purpose, even more monocytes showed up. That seems backwards — but it hints at something important. Neutrophils don't just fight infection; they also release "proresolving" molecules that act like brakes, telling the immune system to calm down and start healing. Without those brakes, the retina kept calling for more and more reinforcements.
That insight led to the study's most exciting possibility. Instead of wiping out neutrophils entirely — which would never be safe for a non-life-threatening condition — the team used a special blocking antibody against PECAM. This didn't destroy the helpful cells; it simply controlled the flow of traffic through the gate. The result was fewer neutrophils, T cells and monocytes clumping in the retina, and better outcomes in the mice.
Today's treatments for uveitis rely on corticosteroids and broad-spectrum anti-infective drugs, both limited by side effects and complications. Understanding the gatekeeper could lead to gentler, more targeted therapies. That matters most in resource-limited parts of the world, where infections cause an estimated 30% to 60% of uveitis cases and the disease rarely resolves on its own — often turning into a chronic, recurring problem that takes four to six weeks to heal even with treatment.
"We are beginning to realize," says study leader William A. Muller of Northwestern, "that neutrophils that enter a site of inflammation also secrete proresolving mediators that help limit inflammation and promote recovery." The next step, he adds, is turning this understanding into a therapy that could ease suffering far beyond Chicago.